Skip to main content
Premium Trial:

Request an Annual Quote

Health Canada Licenses Qiagen's Hepatitis B Viral Load Assay


NEW YORK (GenomeWeb News) – Qiagen said today that Health Canada has licensed its artus PCR-based hepatitis B virus assay to monitor the viral load of HBV-infected patients.
 
The company said that the assay kit is in compliance with Health Canada's medical device requirements and is now available to doctors in Canada to help evaluate the efficacy of treatment.
 
Qiagen said that the kit is configured for Roche’s LightCycler RT-PCR instrument and includes reagents to detect the HBV genotypes A-G. The company said these genotypes are “representative of strains of the virus which can be found globally, ensuring highest sensitivity in monitoring of treatments.”
 
Financial terms of the agreement were not provided.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.